Back to library
Loading…
cognition · Journal of Experimental Medicine · 2024
A phase 2a trial of LM11A-31 showed positive effects on neurodegeneration markers and cognitive decline in early Alzheimer's disease.
Longo, F. M., et al.
A phase 2a trial of LM11A-31 showed positive effects on neurodegeneration markers and cognitive decline in early Alzheimer's disease.